Related Experiment Video

Updated: Aug 30, 2025

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.5K

Reduced PTCH2 expression is associated with glioma development through its regulation of the PTEN/AKT signaling

Jizhong Han1, Huajiang Deng1, Yu Xiong1

  • 1Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China; Sichuan Clinical Research Center for Neurosurgery, Luzhou, 646000, China; Laboratory of Neurological Disease and Brain Function, Luzhou, 646000, China.

Biochemical and Biophysical Research Communications
|August 26, 2022
PubMed

Insights

Reduced PTCH2 expression correlates with poor glioma prognosis. Restoring PTCH2 suppresses glioma growth by upregulating PTEN and inhibiting AKT, offering new therapeutic strategies for brain tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Mutations in the human protein patched homolog (PTCH) gene are linked to various cancers.
  • The specific role of PTCH2 in glioma development and its underlying mechanisms are not well understood.

Purpose of the Study:

  • To investigate the expression and function of PTCH2 in glioma.
  • To elucidate the molecular mechanisms by which PTCH2 influences glioma progression.
  • To explore PTCH2 as a potential therapeutic target for glioma.

Main Methods:

  • Analysis of PTCH2 expression in The Cancer Genome Atlas (TCGA) database and clinical glioma samples.
  • In vitro experiments involving overexpression of PTCH2 in glioma cell lines (LN229, U87-MG).
  • Investigation of the PTCH2/PTEN/AKT signaling pathway.
  • In vivo studies using tumor-bearing mice to assess therapeutic strategies.

Main Results:

  • Lower PTCH2 expression was observed in glioma patients with poor prognoses.
  • Overexpression of PTCH2 inhibited glioma cell proliferation and invasion.
  • PTCH2 was found to upregulate tumor suppressor PTEN, subsequently suppressing pro-survival AKT signaling.
  • Reduced PTEN and elevated AKT expression promoted glioma development in vitro and in vivo.
  • Blocking PTCH2/AKT signaling enhanced chemotherapy efficacy and prolonged survival in mice.

Conclusions:

  • PTCH2 acts as a tumor suppressor in glioma by regulating the PTEN/AKT pathway.
  • PTCH2 expression levels are a potential prognostic biomarker for glioma.
  • Targeting the PTCH2/AKT signaling axis presents a promising therapeutic strategy for glioma treatment.
Keywords:
AKTGliomaPTCH2PTEN

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K